Home › Compare › SYHLF vs ABBV
SYHLF yields 0.85% · ABBV yields 3.06%● Live data
📍 ABBV pulled ahead of the other in Year 1
Combined, SYHLF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of SYHLF + ABBV for your $10,000?
Symphony Holdings Limited, an investment holding company, primarily operates as a retailing company. It operates through Branding, Retailing, and Financial Services segments. The company is involved in the retailing and provision of sourcing services for branded apparel, swimwear, and accessories; manufacturing and trading of healthcare products; and development and management of PONY and SKINS trademarks. It also manages and operates outlet malls, duty free shops, and fashion stores; and provides securities brokerage, margin financing, underwriting and placing, financial consulting, and money lending services. In addition, the company offers information, technology, corporate, and portfolio management services; accountancy, legal, secretarial, and cruiser services; and online trading platform support services. Further, it engages in the trading, retailing, and distribution of swimming apparel and accessories; property investment and holding activities; holding of club debentures; sub-licensing of trademark rights; and trading and wholesaling of sportswear. It operates in the People's Republic of China, Hong Kong, other Asian countries, the United States, the United Kingdom, and internationally. The company was formerly known as Liang Shing (Holdings) Limited and changed its name to Symphony Holdings Limited in 1997. Symphony Holdings Limited was incorporated in 1993 and is based in North Point, Hong Kong.
Full SYHLF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.